2009 Form 990-PF - Bill & Melinda Gates Foundation

BILL & MELINDA GATES FOUNDATION 56-2618866
FORM 990PF, PART XV - GRANTS AND CONTRIBUTIONS PAID DURING THE YEAR
RELATIONSHIP TO SUBSTANTIAL CONTRIBUTOR
AND
ATTACHMENT 18 (CONT'D)
RECIPIENT NAME AND ADDRESS FOUNDATION STATUS OF RECIPIENT PURPOSE OF GRANT OR CONTRIBUTION AMOUNT
UNIVERSITY OF MARYLAND NONE TO GUIDE DEVELOPMENT OF BROADLY EFFECTIVE
200,000.
685 W BALTIMORE ST 170(C)(1)
BALTIMORE, MD 21201
VACCINES AGAINST ENTERIC INFECTIONS BY
MEASURING ETIOLOGY AND BURDEN OF SEVERE
DIARRHEA AMONG YOUNG CHILDREN IN DEVELOPING
COUNTRIES
UNIVERSITY OF MARYLAND NONE TO DEVELOP RAPID, HIGH THROUGHPUT METHODS TO
1,682,803.
685 W BALTIMORE ST 170(C)(1)
BALTIMORE, MD 21201
ASCERTAIN THE BURDEN AND ETIOLOGY OF ENTERIC
DISEASE IN DEVELOPING COUNTRIES
UNIVERSITY OF MARYLAND BALTIMORE NONE TO DEVELOP A VACCINE IN BOTH DEVELOPING AND
2,066,649.
620 W LEXINGTON ST 4TH FLOOR 170(C)(1)
BALTIMORE, MD 21201
DEVELOPED NATIONS THAT PREVENTS THE
TRANSMISSION OF HIV, THE VIRUS THAT CAUSES
UNIVERSITY OF MISSISSIPPI NONE LARRY WALKER OF THE UNIVERSITY OF MISSISSIPPI
100,000.
PO BOX 1848 509(A)(1)
UNIVERSITY, MS 38677
AIDS.
IN THE U.S. WILL TEST AN INNOVATIVE APPROACH
TO MITIGATE THE TOXICITY OF PRIMAQUINE, A
PROMISING AND POWERFUL MALARIA DRUG. WALKER
WILL SEPARATE THE DRUG INTO TWO COMPONENTS,
CALLED ISOMERS, TO SEE IF A SINGLE FORM
RETAINS THE ABILITY TO ELIMINATE THE MALARIA
PARASITE IN ITS LATENT LIVER STAGES AND THE
MATURE GAMETOCYTES WHILE REDUCING TOXIC SIDE
UNIVERSITY OF NEW MEXICO NONE BRYCE CHACKERIAN AND DAVID PEABODY AT THE
100,000.
915 CAMINO DE SALUD 170(C)(1)
ALBUQUERQUE, NM 87131
FOR PUBLIC DISCLOSURE
294 OF 519
EFFECTS.
UNIVERSITY OF NEW MEXICO IN THE U.S. HAVE
DEVELOPED A NEW PHAGE DISPLAY SYSTEM BASED ON
HIGHLY IMMUNOGENIC VIRUS-LIKE PARTICLES
(VLPS), AND WILL UTILIZE THIS NEW SYSTEM AS A
PLATFORM TO IDENTIFY NEW VACCINES THAT INDUCE
BROADLY NEUTRALIZING ANTIBODIES AGAINST HIV.
ATTACHMENT 18